Biotechnology at Inter American University of Puerto Rico-Aguadilla

A debt-to-earnings ratio of 0.51 suggests manageable borrowing, but these figures come with substantial uncertainty—both earnings and debt are estimated from peer programs nationally since this specific program's graduate cohort is too small for the DOE to publish. For a school serving a predominantly Pell-eligible population (84%), understanding the true financial outcomes matters enormously.

What we can say is that peer biotechnology bachelor's programs nationally suggest first-year earnings around $47,000, while similar programs at this institution type typically leave graduates with $24,000 in debt—notably higher than Puerto Rico's typical biotech debt of $14,000. That gap could reflect differences in financial aid packaging or student need. The field itself shows consistent early-career earnings nationally, but biotechnology outcomes can vary widely depending on whether graduates land in research labs, pharmaceutical manufacturing, or quality control roles, and Puerto Rico's biomedical sector has its own distinct employment landscape.

The bottom line: this program's actual outcomes remain unknown due to small cohort sizes. If your child is considering this path, you'll need to dig deeper—talk to current students and recent graduates about job placement, connect with Puerto Rico's pharmaceutical employers directly, and understand whether the estimated $24,000 debt reflects typical borrowing at this campus. The estimates suggest reasonable positioning, but they're only as reliable as the assumption that this program mirrors national peers.